A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need
AffiliationDorset Cancer Centre, Poole NHS Foundation Trust, Longfleet Road, Poole, BH15 2LB, UK.
MetadataShow full item record
AbstractBACKGROUND: There is absence of literature related to cough prevalence and its characteristics in lung cancer patients, with information deriving only from broader symptoms occurrence studies. The aims of this study were to provide a snapshot of the prevalence of all-cause-cough in lung cancer patients and to characterise cough in terms of its impact and severity. METHODS: A cross-sectional study recruiting consecutive lung cancer patients over a pre-defined period of time and using cough-specific validated tools in a tertiary referral centre in the UK, including a cough severity VAS and the Manchester Cough in Lung Cancer scale (MCLCS). RESULTS: Data was collected from 202 patients. All-cause cough prevalence was 57% (through VAS) both in the screened (N =?223) and research (N =?202) population or 67% (through the MCLCS), and cough severity was moderate at a mean of 32?mm (in a 100?mm VAS). Age, sex, smoking status, lung cancer histology, stage and comorbidities were not associated with cough prevalence. The only variable associated with lower cough reports was being 'on anticancer treatment'; fewer patients on treatment reported a cough (40%) compared to those off treatment (54%) (p =?0.04). The impact of cough (as measured by MCLCS) was also significant (mean score?=?22). About 18% of patients felt moderate/severe distress from their cough and about 15% often or always reported disturbed sleep due to coughing. Half the patients felt their cough warranted treatment. CONCLUSIONS: Cough is a common symptom in lung cancer with considerable impact on patients' lives. Cough presence and severity should regularly be assessed in clinical practice. There is an urgent need to focus on developing more potent antitussive treatments and improve the management of this complex and distressing symptom.
CitationHarle A, Molassiotis A, Buffin O, Burnham J, Smith J, Yorke J, et al. A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need. BMC Cancer. 2020;20(1):9.
- Validation of the Japanese version of the Manchester Cough in Lung Cancer Scale.
- Authors: Kishimoto Y, Shirai T, Akamatsu T, Suzuki T, Asada K, Kanemitsu Y, Niimi A
- Issue date: 2021 May 14
- Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity.
- Authors: Lee H, Jhun BW, Cho J, Yoo KH, Lee JH, Kim DK, Lee JD, Jung KS, Lee JY, Park HY
- Issue date: 2017
- Cough in Patients With Lung Cancer: A Longitudinal Observational Study of Characterization and Clinical Associations.
- Authors: Harle ASM, Blackhall FH, Molassiotis A, Yorke J, Dockry R, Holt KJ, Yuill D, Baker K, Smith JA
- Issue date: 2019 Jan
- Understanding cough and its management in lung cancer.
- Authors: Harle AS, Blackhall FH, Smith JA, Molassiotis A
- Issue date: 2012 Jun
- Lung Cancer in the Young.
- Authors: Galvez-Nino M, Ruiz R, Pinto JA, Roque K, Mantilla R, Raez LE, Mas L
- Issue date: 2020 Feb